

Drug	mechanism	effect	clinically	Side effect
Glucocorticoid	<ul style="list-style-type: none"> - inhibit genes codes for cytokines (IL-2) - causing B cells to produce IL-2 and its receptor 	<ul style="list-style-type: none"> - Suppress cell mediated immunity and humoral immunity - anti-inflammatory 	<ul style="list-style-type: none"> - first line Immune suppressive for transplant → solid and APS cells - GVHD - thrombocytopenic purpura - RA - allergic rxn (asthma) - Pre medication. 	<ul style="list-style-type: none"> - immune deficiency - Adrenal glands (secretion) - Hyperglycemia (redistribution fat) - osteoporosis - ↓ growth → Delayed Abirity - excitatory → CVS - cataracts - gastric ulcers (← omeprazole misoprostol)
Calcineurin Inhibitors Cyclosporine Tacrolimus	<ul style="list-style-type: none"> - inhibit Calcineurin (cytosolic Phosphatase) which activates TF NFAT → ⊖ synthesis of IL [IL-2] 	<ul style="list-style-type: none"> - suppress cell mediated immunity 	<ul style="list-style-type: none"> - human organ transplantation - GVHD after hematoblastic stem cells - selected autoimmune diseases. ↳ uveitis, RA, Psoriasis, Asthma - Dry eye Syndrome, ocular GVHD - Dermatologic Diseases [Psoriasis Dermatitis] 	<ul style="list-style-type: none"> - High dose: toxicity (nephro, mental, hyperglycemia, hyper tension) } narrow TW - low dose: rejection - Acute: cataracts - Hyperlipidemia - Diabetes
m-TOR inhibitor Sirolimus Rapamune	<ul style="list-style-type: none"> - inhibit kinase activity of Rapamycin (mTOR) and decrease IL-2 activity 	<ul style="list-style-type: none"> - Inhibit immune cell growth 	<ul style="list-style-type: none"> - combined with cyclosporine increase plasma level of sirolimus ← monitor 	<ul style="list-style-type: none"> - narrow TW - High dose: Toxicity (nephro, mental) - low dose: rejection
Anti-metabolites methotrexate Azathioprine Mycophenolate	<ul style="list-style-type: none"> - at low doses for immune therapy [High dose → anti cancer] - folic acid analogue → bind dihydrofolate reductase → prevent synthesis of Tetrahydrofolate → Depletion of Purines. - Reversible inhibitor of Inosine mono Phosphate DH [IMPDH] → Depletion of G nucleotides. 	<ul style="list-style-type: none"> - affect the Proliferation of B and T cells. - main immunosuppressive cytotoxic substance - anti proliferative effect of B, T cells. 	<ul style="list-style-type: none"> - treatment of autoimmune (RA, Behcet's Disease) and in transplantations. - extensively used in control transplant rejection reactions - used in combination with cyclosporine and prednisolone - mycophenolate mofetil → solid transplantation for refractory rejection - mycophenolate with pred... → Don't use it w/ cyclosporine they tolerate it - low dose cyclosporin with myco, in renal transplant pre cyclosporin → nephrotoxicity. 	<ul style="list-style-type: none"> - narrow TW - High dose: Toxicity (nephro, mental) - low dose: rejection
Immunosuppressive antibodies muromonab (anti CD3)	<ul style="list-style-type: none"> - anti CD3 in T cell - anti IL-2 R → Block Proliferation T cells 	<ul style="list-style-type: none"> - suppressive the activity of T cells - Block co-stimulatory signals. - rapid depletion of mature T cells 	<ul style="list-style-type: none"> - Deplete T cells from bone marrow prior the transplantation. - treat acute rejection of renal allograft - corticosteroid-resistance acute allograft rejection of cardiac and hepatic transplant patients. - prevent acute rejection in renal trans. - treat bone marrow before trans. - 2 doses: 1st before 2H of isg, 2nd after 4 days of isg ↳ patient with expected delayed graft function and in higher risk of rejection for people not respond to methotrexate, to slow RA combined with methotrexate to treat RA when anti TNFα fail with some patients. give in atopic asthma as last choice 	<ul style="list-style-type: none"> - initially activate T cells → cytokine storm → treat by pre mediate: methylprednisolone, Diphenhydramine, acetaminophen - major toxicity in GI - latent TB - worsening the congestive heart failure
Anti IL-2 R Basiliximab Daclizumab	<ul style="list-style-type: none"> - Half life: 7 days - 20 days, blockade 120 days. 			
anti TNFα Infliximab Adalimumab	<ul style="list-style-type: none"> - anti TNFα - anti B cell [CD 20] 			
Rituximab				
Omalizumab	<ul style="list-style-type: none"> - anti Ig-E 			

better

more effective in prevention of acute rejection

better

po

normal case consist of

- Tacrolimus → 2 doses means Half life short
- Prednisolone → 1 dose " " " long
- Azathioprine → 1 dose " " " "

when increase risk of rejection

- Tacrolimus led triple therapy, but with MMF substituted for Azathioprine.
 - ↳ given 2 doses

Immunostimulant

↳ Interferon

- ↳ INF α, β → antiviral
- ↳ INF γ → immunomodulating

side effect: flu-like symptoms, fatigue, malaise

↳ IL-2

- ↳ Help in T cell proliferation and other cells.
- treat melanoma, Renal cell carcinoma, Hodgkin disease.

Cancer immunotherapy

- ↳ anti PD-1 → nivolumab
- ↳ anti CTLA4 → Ipilimumab.

Trough levels

↳ indicate the eliminating rate of the Drug

لازم قبل جرعة كل ١١-١٥ يوم

Tacrolimus وجرعة ١ وجرعة ١ cyclosporine لا

cyclosporine → metabolise in liver P450 A3 system.